A drug called glecirasib in lung cancer that spread to the brain lining
Original title: Glecirasib treatment in KRAS G12C-positive non-small cell lung cancer with leptomeningeal metastasis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors looked back at the records of seven people, so this was not a planned trial.
The short version
Seven people with lung cancer in the brain lining took a drug called glecirasib.
What was studied. Doctors looked back at the records of seven people treated at one hospital. All had lung cancer with a gene change called KRAS G12C that had spread to the lining of the brain and spinal cord. All of them took a drug called glecirasib.
What they found. In five of the seven people, the cancer in the brain lining got better. In one person it stayed the same, and in one person it got worse. Later, the cancer grew again in two people, and one person died. Tests of the spinal fluid in two people showed the cancer signal dropped after the drug started, then rose again.
What this means, and what it doesn't
What it could mean: This drug may help some people with cancer in the brain lining, which is a very hard problem to treat. It only works on tumors with the KRAS G12C gene change, so a gene test would be needed. Seven people is a very small group, so this is a first hint and not proof.
What it doesn't mean: This does not mean the drug is proven to work. It was not a planned study. Doctors simply looked back at what happened to seven people. A report this small cannot tell us how well the drug works or how long it lasts. It is not a cure, and it does not change the care most people get today. Much larger studies in people would be needed first.
Source: PubMed, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.